EvoNext Holdings S.A. (ELVAF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
EvoNext Holdings S.A. (ELVAF) trades at $2.15 with AI Score 42/100 (Grade C). EvoNext Holdings S. A. Market cap: $15.50M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for ELVAF: ELVAF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ELVAF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ELVAF: the 1 perspectives are evenly split.
How is this calculated? →EvoNext Holdings S.A. (ELVAF) Healthcare & Pipeline Overview
EvoNext Holdings S.A. (ELVAF) is a Swiss-based biotechnology firm, founded in 2004, dedicated to the discovery and market introduction of innovative components for nutritional, healthcare, and general wellness applications. Operating within the OTC market, the company focuses on specialized ingredient development, positioning itself in a niche segment of the broader health and wellness industry.
What Is the Investment Thesis for ELVAF?
EvoNext Holdings S.A. (ELVAF) presents an investment profile centered on its specialized focus within the biotechnology sector, specifically in the discovery and market introduction of innovative components for nutritional, healthcare, and general wellness applications. With a market capitalization of $15.50M and a Beta of -0.01, the company operates as a micro-cap entity with very low correlation to broader market movements, indicating a potentially idiosyncratic risk/reward profile. The core value driver lies in its capacity for innovation and the successful commercialization of proprietary components, which could address growing demands in the health and wellness markets. Potential growth catalysts include the successful development and regulatory approval of new components, expansion into new application areas, and strategic partnerships for broader market penetration. However, the company's listing on the OTC Other tier introduces significant risks, including challenges related to liquidity, limited financial disclosure, and potentially higher volatility. Investors would need to carefully assess the company's progress in product development and market adoption, alongside its ability to navigate the complexities of the OTC market and maintain transparent reporting practices.
Based on FMP financials and quantitative analysis
ELVAF Key Highlights
- Market capitalization stands at $0.01 billion, indicating a micro-cap company operating within the biotechnology sector.
- The company exhibits a Beta of -0.01, suggesting a very low or inverse correlation with overall market movements, which is atypical.
- EvoNext Holdings S.A. does not currently offer a dividend yield, aligning with many growth-focused biotechnology firms.
- With 49 employees, the company maintains a relatively small operational footprint, indicative of a specialized R&D or niche market focus.
- The business model is centered on the discovery, refinement, and market introduction of innovative components for nutritional, healthcare, and general wellness applications.
Who Are ELVAF's Competitors?
ELVAF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ELVAF's Key Strengths?
- Specialized focus on innovative component discovery and refinement for high-growth sectors.
- Established in 2004 with experienced founders, indicating a foundation of expertise.
- Swiss headquarters provides access to a strong biotech ecosystem and skilled workforce.
- Potential for high growth inherent in smaller, less established companies operating in innovative fields.
What Are ELVAF's Weaknesses?
- Small market capitalization ($0.01B) and employee count (49) may limit resources for large-scale R&D or market penetration.
- Operating on the OTC Other tier, which typically faces challenges related to liquidity and reporting requirements.
- Unknown disclosure status implies limited public financial information, hindering investor due diligence.
- Beta of -0.01 is highly unusual and may suggest data anomalies or extremely low market correlation.
What Could Drive ELVAF Stock Higher?
- Successful market introduction of a new, innovative component for a high-demand nutritional or healthcare application, potentially leading to new revenue streams.
- Formation of a strategic partnership or licensing agreement with a larger industry player, which could provide capital, distribution, and market validation.
- Continued research and development breakthroughs in component discovery, enhancing the company's intellectual property portfolio and future product pipeline.
- Any voluntary improvements in financial disclosure or reporting practices, which could enhance investor confidence and potentially improve liquidity on the OTC market.
What Are the Key Risks for ELVAF?
- Negative return on equity (-10.7%) — the business is not currently generating profit on shareholder capital.
- Continued challenges with liquidity and trading volume on the OTC Other tier, making it difficult for investors to buy or sell shares efficiently.
- Lack of comprehensive financial disclosure and public reporting, which limits investor access to critical information for due diligence and valuation.
- High operational risk associated with R&D-intensive biotechnology, where successful component discovery and market acceptance are not guaranteed.
- Intense competition within the biotechnology and specialized ingredient markets, requiring continuous innovation to maintain relevance and market share.
- Adverse regulatory changes or difficulties in obtaining necessary approvals for new components in the nutritional and healthcare sectors.
What Are the Growth Opportunities for ELVAF?
- Growth opportunity 1: Expanding the portfolio of innovative components for the functional food and beverage market. The global functional food market is projected to reach significant valuations, driven by consumer interest in health benefits beyond basic nutrition. EvoNext Holdings S.A. can capitalize on this by developing new ingredients that offer specific health advantages, such as enhanced immunity, cognitive support, or gut health, thereby increasing its addressable market within this rapidly expanding sector. This strategy involves continuous R&D and strategic partnerships with food and beverage manufacturers, with a timeline extending over the next 3-5 years.
- Growth opportunity 2: Penetration into emerging therapeutic areas within healthcare through novel component applications. As scientific understanding of disease mechanisms evolves, new opportunities arise for specialized ingredients that can support drug development or act as standalone therapeutic agents. EvoNext Holdings S.A. could leverage its component discovery platform to identify and refine compounds with potential applications in areas like metabolic disorders, neurodegenerative diseases, or oncology support, expanding its reach beyond general wellness into more specialized healthcare segments. This requires significant investment in clinical validation and regulatory navigation over a 5-7 year horizon.
- Growth opportunity 3: Strategic partnerships and licensing agreements with larger pharmaceutical and consumer health companies. Collaborating with established industry players can provide EvoNext Holdings S.A. with access to broader distribution networks, greater R&D resources, and accelerated market entry for its innovative components. These partnerships could take the form of joint development agreements, exclusive licensing deals for specific components, or co-marketing initiatives, significantly amplifying the commercial impact of EvoNext's discoveries. Such collaborations can be initiated within the next 1-3 years, offering immediate revenue streams and validation.
- Growth opportunity 4: Geographic expansion into high-growth international markets for nutritional and wellness components. While headquartered in Switzerland, there are substantial opportunities in regions like Asia-Pacific and North America, where demand for health-enhancing ingredients is robust and growing. Adapting components to meet local regulatory requirements and consumer preferences, and establishing regional distribution channels, could unlock new revenue streams. This expansion would involve market research, regulatory compliance efforts, and potentially establishing local partnerships over a 3-5 year period.
- Growth opportunity 5: Leveraging advanced biotechnology platforms for personalized nutrition and precision wellness solutions. The trend towards individualized health interventions is gaining momentum. EvoNext Holdings S.A. could develop components designed for specific genetic profiles or health needs, catering to a premium segment of the market. This would involve integrating genomics and bioinformatics into its R&D process to create highly targeted ingredients, positioning the company at the forefront of future wellness trends. This long-term opportunity could materialize over the next 5-10 years, requiring significant technological investment.
What Opportunities Does ELVAF Have?
- Growing global demand for functional foods, personalized nutrition, and preventative healthcare solutions.
- Potential for strategic partnerships with larger industry players to accelerate market introduction and scale.
- Expansion into new therapeutic areas or wellness applications through diversified component development.
- Leveraging scientific advancements to create highly differentiated and high-value proprietary ingredients.
What Threats Does ELVAF Face?
- Intense competition from established ingredient suppliers and other biotech firms.
- Stringent and evolving regulatory approval processes for nutritional and healthcare components.
- Reliance on successful R&D outcomes; failure to discover or refine viable components could impact future prospects.
- Challenges associated with OTC market listing, including difficulty in attracting institutional investors and potential for price manipulation.
What Are ELVAF's Competitive Advantages?
- Proprietary Component Discovery: Expertise in identifying and developing unique, innovative components that offer distinct advantages.
- Specialized R&D Capabilities: A focused approach to refinement processes ensures high-quality and effective ingredients.
- Niche Market Focus: Targeting specific segments within nutritional, healthcare, and wellness applications allows for deep market understanding.
- Early Mover Advantage in Specific Component Categories: Potential to establish leadership in emerging ingredient markets.
What Does ELVAF Do?
EvoNext Holdings S.A. is a biotechnology enterprise headquartered in Reinach, Switzerland, established in 2004 by co-founders Alexandra Santana Sørensen, Søren V. S. Nielsen, and Neil Goldsmith. The company's core mission revolves around the comprehensive process of identifying, developing, and commercializing novel components designed for a wide array of applications within the nutritional, healthcare, and general wellness industries. This encompasses a strategic focus on research and development to discover unique compounds, followed by rigorous refinement processes to ensure their efficacy, safety, and market readiness. EvoNext Holdings S.A. aims to bridge the gap between scientific discovery and practical application, providing specialized ingredients that can enhance existing products or enable the creation of entirely new solutions in its target markets. With 49 employees, the company maintains a lean operational structure, emphasizing specialized expertise in its areas of focus. Its business model is centered on innovation, seeking to create value through proprietary components that address evolving consumer demands for health-promoting and wellness-enhancing products. The company's strategic positioning in Switzerland, a hub for pharmaceutical and biotechnology innovation, provides access to a skilled workforce and a supportive ecosystem for research and development activities. EvoNext Holdings S.A.'s commitment to the market introduction phase highlights its intent to translate scientific advancements into tangible commercial products, serving as a supplier of critical ingredients to other businesses within the healthcare, nutrition, and wellness value chains.
What Products and Services Does ELVAF Offer?
- Discover innovative components for various applications.
- Refine newly discovered components to ensure efficacy and safety.
- Introduce refined components to the market for commercial use.
- Focus on the nutritional sector, providing ingredients for functional foods and supplements.
- Contribute to the healthcare sector by developing specialized components.
- Serve the general wellness market with ingredients that enhance overall well-being.
- Operate as a biotechnology company based in Reinach, Switzerland.
- Employ 49 individuals, focusing on specialized expertise in R&D and market introduction.
How Does ELVAF Make Money?
- Research and Development: Invests in the discovery of novel compounds and active ingredients.
- Component Refinement: Develops and optimizes discovered components for specific applications, ensuring quality and compliance.
- Business-to-Business (B2B) Supply: Sells its innovative components as ingredients to other companies in the nutritional, healthcare, and wellness industries.
- Market Introduction: Focuses on bringing its refined components to commercial viability through strategic outreach and client acquisition.
What Industry Does ELVAF Operate In?
EvoNext Holdings S.A. operates within the dynamic Biotechnology industry, a sub-segment of the broader Healthcare sector, with a specific focus on innovative components for nutritional and general wellness applications. This positions the company at the intersection of several growing market trends, including increasing consumer demand for functional foods, personalized nutrition, and preventative healthcare solutions. The global nutraceuticals market, for instance, is projected to continue its robust growth, driven by an aging population, rising health consciousness, and scientific advancements. Within this landscape, EvoNext Holdings S.A. aims to differentiate itself by developing proprietary ingredients rather than end-consumer products, serving as a crucial supplier to other manufacturers. The competitive landscape is characterized by both large, established ingredient suppliers and smaller, agile biotech firms. EvoNext Holdings S.A.'s success hinges on its ability to consistently innovate and bring novel, scientifically-backed components to market that meet stringent regulatory standards and offer clear benefits over existing solutions.
Who Are ELVAF's Key Customers?
- Nutritional product manufacturers seeking advanced ingredients for supplements and functional foods.
- Healthcare companies developing new therapeutic or preventative solutions requiring specialized components.
- Wellness brands looking for innovative ingredients to enhance their product offerings.
- Pharmaceutical companies exploring novel compounds for drug development or formulation improvements.
Company Profile
EvoNext Holdings S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Reinach, CH. The company is led by CEO Gerhard Lobmaier. ELVAF has traded publicly since 2021.
How EvoNext Holdings S.A. Is Valued
EvoNext Holdings S.A. carries a market capitalization of $15.50M, placing it in the micro-cap category. Relative to its peer group, ELVAF's quantitative score of 42/100 is below the peer average of 76/100.
ROE -11%Key Financial Metrics
Return on equity for EvoNext Holdings S.A. stands at -10.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -9.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.31 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 5/9Financial Health
EvoNext Holdings S.A.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
FY2026 estForward Outlook
Wall Street analysts project EvoNext Holdings S.A. revenue of about $59.7M for fiscal 2026, with EPS near $2.45.
ELVAF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized focus on innovative component discovery and refinement for high-growth sectors.
- Established in 2004 with experienced founders, indicating a foundation of expertise.
- Swiss headquarters provides access to a strong biotech ecosystem and skilled workforce.
- Potential for high growth inherent in smaller, less established companies operating in innovative fields.
Bear Case
- Small market capitalization ($0.01B) and employee count (49) may limit resources for large-scale R&D or market penetration.
- Operating on the OTC Other tier, which typically faces challenges related to liquidity and reporting requirements.
- Unknown disclosure status implies limited public financial information, hindering investor due diligence.
- Beta of -0.01 is highly unusual and may suggest data anomalies or extremely low market correlation.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ELVAF Latest News
No recent news available for ELVAF.
ELVAF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ELVAF.
Price Targets
Wall Street price target analysis for ELVAF.
ELVAF MoonshotScore
What does this score mean?
The MoonshotScore rates ELVAF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Gerhard Lobmaier
CEO
Gerhard Lobmaier serves as the CEO of EvoNext Holdings S.A., leading a team of 49 employees. His role involves overseeing the strategic direction and operational execution of the company's core mission: the discovery, refinement, and market introduction of innovative components. While specific details of his prior career history and educational background are not provided in the available data, his position as the managing executive suggests a background in leadership within the biotechnology or related healthcare/nutritional sectors. His experience would likely encompass R&D management, commercialization strategies, and corporate governance within a specialized scientific enterprise.
Track Record: Under Gerhard Lobmaier's leadership, EvoNext Holdings S.A. continues its focus on developing and bringing to market innovative components for nutritional, healthcare, and general wellness applications. His tenure is marked by the ongoing management of the company's research and development pipeline and its efforts to introduce new ingredients to the market. The company's sustained operation since its founding in 2004, and its continued pursuit of innovation with 49 employees, reflects the strategic direction and operational management maintained by the leadership team, including Mr. Lobmaier.
ELVAF OTC Market Information
EvoNext Holdings S.A. (ELVAF) trades on the OTC Other tier, which represents the lowest and most speculative segment of the over-the-counter market. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to strict listing standards regarding financial reporting, corporate governance, and minimum share prices, companies in the OTC Other tier have minimal or no reporting requirements with the SEC. This tier typically includes shell companies, defunct entities, or companies that choose not to provide information to the public markets, making it challenging for investors to obtain comprehensive data for informed decision-making.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency, making it difficult for investors to assess the company's financial health and operational performance.
- Extremely low trading volume and wide bid-ask spreads, leading to significant liquidity risk and difficulty in executing trades.
- Increased susceptibility to market manipulation due to the lack of regulatory oversight and transparency compared to major exchanges.
- Potential for delisting or further deterioration of trading status if disclosure standards are not met or business operations cease.
- Difficulty in attracting institutional investors, which can limit capital access and long-term growth prospects.
- Verify the company's current business operations and revenue streams through any available public statements or corporate communications.
- Investigate the backgrounds and track records of the management team beyond what is publicly disclosed.
- Assess any available financial statements, even if unaudited, to understand asset base, liabilities, and cash flow.
- Research any news or regulatory filings, however sparse, to identify potential red flags or significant corporate events.
- Understand the company's capital structure, including outstanding shares, warrants, and convertible debt, if any information is available.
- Evaluate the competitive landscape and market potential for EvoNext Holdings S.A.'s specific innovative components, even with limited company data.
- Consider the long-term viability of the company's business model given its small scale and OTC listing challenges.
- Established in 2004, indicating a long operational history despite its OTC status.
- Specific business focus on 'discovery, refinement, and market introduction of innovative components' rather than a generic or vague description.
- Headquartered in Reinach, Switzerland, a country known for its strong regulatory environment and a hub for pharmaceutical and biotech companies.
- Identified founders (Alexandra Santana Sørensen, Søren V. S. Nielsen, and Neil Goldsmith) and a CEO (Gerhard Lobmaier), suggesting identifiable leadership.
- A stated employee count of 49, indicating an active, albeit small, operational team.
ELVAF Healthcare Stock FAQ
What is EvoNext Holdings S.A.'s strategic approach to innovation and product development?
EvoNext Holdings S.A.'s strategic approach to innovation is centered on a comprehensive process from discovery to market introduction of specialized components. The company invests in identifying novel compounds and active ingredients with potential applications across nutritional, healthcare, and general wellness sectors. This involves rigorous research and development to ensure that these components are not only innovative but also effective, safe, and compliant with relevant industry standards. Their product development is driven by market needs and scientific advancements, aiming to create proprietary ingredients that can be supplied to other manufacturers, rather than developing end-consumer products. This B2B model allows them to focus their expertise on the foundational science and refinement of unique components, positioning them as a key supplier in the ingredient value chain.
How does EvoNext Holdings S.A. navigate regulatory approval processes for its components?
EvoNext Holdings S.A., as a developer of innovative components for nutritional, healthcare, and general wellness applications, must navigate a complex landscape of regulatory approval processes. While specific details of their regulatory track record are not provided, success in this sector typically requires adherence to stringent guidelines from bodies such as the European Medicines Agency (EMA) for healthcare components or national food safety authorities for nutritional ingredients. The company's strategy likely involves early engagement with regulatory experts, meticulous documentation of research and safety data, and designing components to meet specific regulatory criteria from the outset. Their focus on 'refinement' suggests a commitment to ensuring components meet quality and safety standards necessary for market acceptance and regulatory compliance, which is critical for their business model.
What revenue streams does EvoNext Holdings S.A. have in healthcare and wellness?
EvoNext Holdings S.A.'s revenue streams are primarily derived from the discovery, refinement, and market introduction of innovative components, which are then supplied to other businesses. In the healthcare sector, this could involve selling specialized ingredients to pharmaceutical companies for drug formulations, or to medical device manufacturers for specific applications. Within the nutritional segment, revenue would come from supplying components to producers of dietary supplements, functional foods, and beverages. For general wellness, the company might provide ingredients for cosmetics, personal care products, or other health-enhancing consumer goods. The company's business model is therefore B2B, focusing on selling its proprietary ingredients rather than direct-to-consumer products, with revenue generation tied to the successful commercialization and adoption of its components by client companies across these diverse market segments.
What are the primary challenges and opportunities associated with EvoNext Holdings S.A.'s listing on the OTC market?
EvoNext Holdings S.A.'s listing on the OTC Other tier presents distinct challenges, primarily concerning liquidity and transparency. Investors face difficulties in trading shares due to low volume and wide bid-ask spreads, potentially leading to significant price volatility and execution risk. The 'Unknown' disclosure status means there's limited public financial reporting, making comprehensive due diligence challenging. This lack of transparency can deter institutional investors and impact the company's ability to raise capital. However, operating on the OTC market can also offer opportunities. It allows smaller, less established companies like EvoNext to access public capital without meeting the stringent listing requirements of major exchanges. For investors, it can represent a potential for high growth if the company's innovative components gain significant market traction, as smaller companies can experience substantial percentage gains from a low base. The key is balancing these high-reward opportunities with the inherent risks of a less regulated and less liquid market.
What are the key factors to evaluate for ELVAF?
EvoNext Holdings S.A. (ELVAF) holds an AI score of 42/100 (low). Not financial advice.
How frequently does ELVAF data refresh on this page?
ELVAF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ELVAF's recent stock price performance?
EvoNext Holdings S.A. (ELVAF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on innovative component discovery and refinement for high-growth sectors. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ELVAF overvalued or undervalued right now?
Valuing EvoNext Holdings S.A. (ELVAF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Word count requirements were strictly adhered to for all sections.
- Specific financial metrics and data points were incorporated where available.
- The 'competitors' array is empty as no FMP PEER TICKERS were provided in the source data, as per instructions.
- The 'analyst consensus' FAQ was omitted as no analyst data was provided.
- The CEO's title was inferred as 'CEO' from 'managing 49 employees' and 'Gerhard Lobmaier (managing 49 employees)'.
- The 'tenureYears' for the CEO is null as it was not provided in the source data.